公开(公告)号：US11655241B2

公开(公告)日：2023-05-23

申请号：US16973320

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tsuneo Oda ,  Yoshiteru Ito ,  Tohru Miyazaki ,  Kohei Takeuchi ,  Norihito Tokunaga ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura ,  Yuichi Kajita ,  Yuhei Miyanohana ,  Takahiro Sugimoto ,  Tatsuki Koike ,  Dilhumar Uyghur

IPC: C07D405/12 ,  C07D207/14 ,  C07D211/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/14 ,  C07D417/06 ,  C07D417/14

CPC classification number: C07D405/12 ,  C07D207/14 ,  C07D211/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/14 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10584097B2

公开(公告)日：2020-03-10

申请号：US16577449

申请日：2019-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  C07D405/06 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D211/36 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US09637483B2

公开(公告)日：2017-05-02

申请号：US14779347

申请日：2014-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshida ,  Hiroyuki Nagamiya ,  Yusuke Ohba ,  Masaki Seto ,  Takatoshi Yogo ,  Satoshi Sasaki ,  Norihito Tokunaga ,  Kazuyoshi Aso

IPC: A61K31/437 ,  C07D401/14 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20150094296A1

公开(公告)日：2015-04-02

申请号：US14388452

申请日：2013-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tetsuya Tsukamoto ,  Yusuke Ohba ,  Takafumi Yukawa ,  Hiroyuki Nagamiya ,  Taku Kamei ,  Norihito Tokunaga ,  Morihisa Saitoh ,  Atsutoshi Okabe

IPC: C07D403/04 ,  C07D401/14 ,  C07D413/14 ,  C07D491/107 ,  C07D403/14 ,  C07D405/14

CPC classification number: C07D403/04 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/107

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣，类风湿性关节炎，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮等）等，其具有优异的Tyk2 抑制作用。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。